Related Experiment Video

Updated: Jun 15, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

Anil Bagri1, Hosein Kouros-Mehr, Kevin G Leong

  • 1Tumor Biology and Angiogenesis Department, Genentech, Inc, One DNA Way, South San Francisco, CA 94080, USA.

Trends in Molecular Medicine
|March 2, 2010
PubMed

Insights

Antiangiogenic therapies aim to cure early-stage cancer patients post-surgery. While promising for advanced cancers, adjuvant antiangiogenesis study results were disappointing, requiring further research for durable effects.

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Clinical Trials

Background:

  • Tumor growth and progression rely on angiogenesis.
  • Antiangiogenic therapies are effective against advanced metastatic cancers.
  • The adjuvant setting aims to improve cure rates after surgical resection.

Purpose of the Study:

  • To evaluate the efficacy of antiangiogenic therapies in the adjuvant setting.
  • To determine if antiangiogenic blockade can increase cure rates in early-stage cancer patients.
  • To address the disappointing results of initial adjuvant clinical studies.

Main Methods:

  • Clinical studies investigating antiangiogenic therapies.
  • Adjuvant treatment strategies following surgical resection.
  • Analysis of patient outcomes and cure rates.

Main Results:

  • Initial clinical studies in the adjuvant setting yielded disappointing results.
  • The efficacy of antiangiogenic blockade in early-stage cancer remains under investigation.
  • Debate exists regarding the potential of this therapeutic approach.

Conclusions:

  • Further clinical studies are necessary to ascertain the durability of antiangiogenic blockade effects.
  • The potential for antiangiogenic therapies to cure a subset of early-stage cancer patients requires additional evidence.
  • The role of antiangiogenesis in the adjuvant setting is currently uncertain.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...